Who is sponsoring NCT06218433?

NCT06218433 is sponsored by Tampere University Hospital.

What drugs are being tested in NCT06218433?

Interventions in NCT06218433: Urothelial cancer screening using urine tumor DNA test, Urothelial cancer screening using urine cytology (comparator).

What condition does NCT06218433 study?

NCT06218433 studies Urothelial Carcinoma, Lynch Syndrome.

Is NCT06218433 still recruiting?

NCT06218433 is currently recruiting now. Last updated 18 November 2025.

Last reviewed 2025-11-18 · How we verify

NCT06218433

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)

Recruiting now NA Last updated 18 November 2025

What this trial tests

NA trial testing Urothelial cancer screening using urine tumor DNA test in Urothelial Carcinoma in 200 participants. Currently enrolling.

Timeline

10 April 2023

Primary endpoint
30 December 2026

31 December 2034

Quick facts

Lead sponsor	Tampere University Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	200
Start date	10 April 2023
Primary completion	30 December 2026
Estimated completion	31 December 2034
Sites	2 locations across Finland, Canada

Drugs / interventions tested

Urothelial cancer screening using urine tumor DNA test
Urothelial cancer screening using urine cytology (comparator)

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Lynch Syndrome — all drugs for Lynch Syndrome →

Sponsor

Tampere University Hospital

Who can join

Adults 50 to 75, any sex, with Urothelial Carcinoma or Lynch Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and endometrial cancers in individuals with LS. Up to one in four LS individuals will develop urothelial cancer during their lifetime, with the risk varying based on the defective MMR gene. In this clinical trial, we will employ urine tumor DNA (utDNA) to identify asymptomatic urothelial cancers in Lynch syndrome patients, and to investigate the potential benefits of urine tumor DNA based screening in this high-risk population.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.
Jaime-Casas S, Tripathi A, Pal SK, Yip W. · · 2024 · cited 6× · PMID 39379745 · DOI 10.1007/s11934-024-01245-1
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500
Abstracts selected for poster presentation [listed in alphabetical order by presenter].
· 2026 · PMID 41625014 · DOI 10.1177/23523735251412131

Verify or expand the search:

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Tampere University Hospital trials

Trials by the same sponsor.

NCT07315568 — Couples and Microbial Diversity · not yet recruiting
NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06218433 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
Last refreshed: 18 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06218433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing